8.42
-0.48 (-5.39%)
| Previous Close | 8.90 |
| Open | 8.79 |
| Volume | 1,377,695 |
| Avg. Volume (3M) | 4,112,900 |
| Market Cap | 660,492,864 |
| Price / Book | 2.39 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -3.07 |
| Total Debt/Equity (MRQ) | 18.32% |
| Current Ratio (MRQ) | 7.95 |
| Operating Cash Flow (TTM) | -192.25 M |
| Levered Free Cash Flow (TTM) | -110.31 M |
| Return on Assets (TTM) | -31.26% |
| Return on Equity (TTM) | -62.58% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Replimune Group, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.13 |
|
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 4.51% |
| % Held by Institutions | 107.50% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 18.00 (Wedbush, 113.78%) | Buy |
| Median | 12.00 (42.52%) | |
| Low | 11.00 (BMO Capital, 30.64%) | Hold |
| 11.00 (JP Morgan, 30.64%) | Hold | |
| Average | 13.00 (54.39%) | |
| Total | 3 Buy, 2 Hold | |
| Avg. Price @ Call | 9.09 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 03 Nov 2025 | 11.00 (30.64%) | Hold | 9.31 |
| HC Wainwright & Co. | 27 Oct 2025 | 12.00 (42.52%) | Buy | 9.33 |
| JP Morgan | 20 Oct 2025 | 11.00 (30.64%) | Hold | 8.95 |
| Leerink Partners | 20 Oct 2025 | 13.00 (54.39%) | Buy | 8.95 |
| Wedbush | 20 Oct 2025 | 18.00 (113.78%) | Buy | 8.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 18 Dec 2025 | Announcement | Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 07 Nov 2025 | Announcement | Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025) |
| 06 Nov 2025 | Announcement | Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update |
| 20 Oct 2025 | Announcement | Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma |
| 19 Oct 2025 | Announcement | Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |